Digital Therapeutics (DTx) Global Market Analysis 2024


The Global Digital Therapeutics (DTx) Market is projected to reach $20.63 billion by 2028, from a value of $4.39 billion in 2022, by registering a CAGR of 29.4% during the forecast period 2022-2028

SKU: ER1080 Category:
© Epson Research 2021
Share this infographic on
Published Year:
Forecast period:
Report Coverage:

Market Trends and analysis of the crucial market segments across North America, Europe, Asia Pacific and Rest of the World.

Report Format:

5 User License

$ 5,500

  • Access to Five users
  • Print upto 5 copies
  • PDF & Excel Formats

Corporate User License

$ 7,000

  • Unlimited users within company
  • Free Yearly update
  • PDF & Excel Formats

The Global Digital Therapeutics (DTx) Market is projected to reach $20.63 billion by 2028, from a value of $4.39 billion in 2022, by registering a CAGR of 29.4% during the forecast period. Increasing incidence of preventable chronic diseases, rising focus on preventive healthcare, and an increase in awareness by government agencies are the major factors propelling the growth of the market. However, Patient data privacy concerns and developing countries lacking smartphones and internet facilities are hampering the market growth. Moreover, significant increases in venture capital investments and unexplored therapeutic applications are creating ample opportunities across the globe.

Recent Developments

In Feb 2022, Teladoc Health launched “Chronic Care Complete” a first-of-its-kind chronic condition management solution to help individuals improve their health outcomes while living with multiple chronic conditions. The solution provides members with a unified, comprehensive experience that leverages connected health monitoring devices, access to health coaches, and support from physicians and mental health specialists when needed.

In April 2021, Welldoc partnered with Dexacom to integrate platforms and offer integrated type 2 diabetes management solutions. This partnership allows bringing together the two most challenging, and often independent, elements of diabetes management – glucose monitoring and the impact of lifestyle choices – for the first time. Through a new app experience, users will be able to manage multiple facets of their health while also improving data sharing with their care team.

In Sep 2020, Click Therapeutics collaborated with Boehringer Ingelheim to develop and commercialize CT-155, a novel prescription digital therapeutic to aid in the treatment of schizophrenia. This collaboration combines Click Therapeutics’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in the clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medical needs.

In Jan 2020, Pear Therapeutics collaborated with Crossroads Treatment Centers. Crossroads Treatment Centers, the parent company of ARS Treatment Centers, will be implementing Pear’s reSET-O® PDT in 38 of its treatment centers across western Pennsylvania this month, with plans to roll out the product across the company’s 10-state footprint throughout 2020.

Competitive Landscape

Wellthy Therapeutics, Ayogo Health, Virta Health, Better Therapeutics, Propeller Health, Click Therapeutics, Omada Health, Mango Health, Inc., Livongo, Hinge Health, CogniFit Ltd., Mindable Health, Canary Health, Pear Therapeutics, BehaVR Inc, Smartpatient, Akili Interactive Labs, Inc., 2Morrow, Inc., Welldoc, Cognoa, and Teladoc are some of the major players in the global Digital Therapeutics (DTx) market.


1 Summary
2 Market Overview
2.1 Abstract
2.2 Research Sources
2.3 Research Findings
2.4 Assumptions
3 Market Dynamics
3.1 Drivers & Opportunities
3.2 Restraints & Threats
3.3 Regulatory Affairs
3.4 Supplychain Analysis
3.5 PORTERS Analysis
4 Competitive Landscape
5 Digital Therapeutics (DTx) Market by Purchase Mode
5.1 Group Purchase Organization
5.2 Individual
6 Digital Therapeutics (DTx) Market by Product and Service Type
6.1 Hardware & Device
6.2 Service
6.3 Solutions/Software
6.3.1 Combination Therapy
6.3.2 Monotherapy
7 Digital Therapeutics (DTx) Market by Sales Channel
7.1 Business-to-Business (B2B)/Fee-for-Service
7.1.1 Pharmaceutical Companies
7.1.2 Healthcare Provider
7.1.3 Employers
7.1.4 Payers
7.2 Business-to-Consumer (B2C)
7.2.1 Caregivers
7.2.2 Patients
8 Digital Therapeutics (DTx) Market by Application
8.1 Management Applications
8.2 Treatment/Care-Related Applications
8.2.1 Smoking Cessation
8.2.2 Central Nervous System (CNS) Disorders Mental Health Disorder Other Central Nervous System (CNS) Disorders
8.2.3 Substance Use & Addiction Management
8.2.4 Chronic Respiratory Disorders
8.2.5 Rehabilitation & Patient Care
8.2.6 Musculoskeletal Disorders
8.2.7 Gastrointestinal Disorders
8.2.8 Cardiovascular Diseases
8.2.9 Medication Adherence
8.2.10 Diabetes
8.3 Preventive Applications
8.3.1 Lifestyle Management
8.3.2 Nutrition
8.3.3 Obesity
8.3.4 Prediabetes
9 Digital Therapeutics (DTx) Market by Regions
9.1 North America
9.2 Europe
9.3 Asia Pacific
9.4 Rest of the World
10 Company Profiles
10.1 Wellthy Therapeutics
10.2 Ayogo Health
10.3 Virta Health
10.4 Better Therapeutics
10.5 Propeller Health
10.6 Click Therapeutics
10.7 Omada Health
10.8 Mango Health, Inc.
10.9 Livongo
10.10 Hinge Health
10.11 CogniFit Ltd.
10.12 Mindable Health
10.13 Canary Health
10.14 Pear Therapeutics
10.15 BehaVR Inc
10.16 Smartpatient
10.17 Akili Interactive Labs, Inc.
10.18 2Morrow, Inc.
10.19 Welldoc
10.20 Cognoa
10.21 Teladoc